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Introduction A lot of effort has been made to investigate the prognostic biomarkers, including epigenetic markers, in cancers, helping to identify high-risk cancer patients who might need adjuvant treatment after surgery. Studies suggest complex genetic and epigenetic profiles of the gastric carcinoma patients, indicating the need for the identification of molecular markers for this tumour type.
Aim The aim of the study was to clarify the role of extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147), CD24 and methylation of p16 promoter in the genesis and progression of gastric carcinoma.
Materials and methods Expression of EMMPRIN (CD147) and CD24 was examined immunohistochemically in tissue sections from gastric carcinoma (n = 80) and noncancerous gastric cases [chronic gastritis with intestinal metaplasia (n = 16) and gastric dysplasia (n = 20)]. In addition, 16 cases of apparently normal gastric were used as control and the expression was compared with clinicopathological parameters of cancer cases, including 5-year survival. The methylation frequency of the p16INK4a promoter was determined by methylation-specific PCR.
Introduction
Gastric cancer is a common gastrointestinal malignancy. Although the incidence of gastric cancer has declined during the past years, it is still the fourth leading cause of cancer-related death. Gastric cancer is the second most frequent cause of cancer-associated death in malignant tumours, accounting for about 10.4% of mortality cases (Tavares et al., 2013) . According to the National Cancer Institute registry, it represents 1.64% of all cancers in Egypt, with a median patient age of 55 years and a male predominance (Anwar et al., 2012) .
Gastric cancer is a multifactorial disease with a complex interplay between genetics and both lifestyle and environmental factors, which consequently result in malignant transformation and progression of gastric cancer. Unfortunately, there has been no specific signature of gastric cancer gene expression reported to allow for patient-tailored therapeutic strategies. Accordingly, there is great demand to further identify novel oncogenes and clinically applicable molecular targets for the diagnosis and treatment of this disease (Guo et al., 2013) .
The degradation of the extracellular matrix (ECM) is critical for cancer cells to invade into surrounding tissue. Matrix metalloproteinases (MMPs) play a critical role in this process (Yu et al., 2008) . Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is a 57-kDa transmembrane glycoprotein that belongs to the immunoglobulin G superfamily. CD147 is composed of two extracellular immunoglobulin domains: a single transmembrane domain required for counterreceptor binding activity, which is involved in MMP induction, and a short cytoplasmic domain that interacts with Cav-1 (Luo et al., 2009) .
For some tumour types, such as pulmonary adenocarcinoma, seminomas, salivary duct carcinoma, prostate cancer, colorectal cancer, bladder cancer and breast cancer, EMMPRIN expression has been seen to be associated with patient prognosis (Pertega-Gomes et al., 2011; Bi et al., 2012; Zhong et al., 2012; Chu et al., 2014) .
CD24 is a cell surface protein that is anchored on the external side of the plasma membrane. It is thought to have an essential role in cell differentiation and is also expressed in cells involved in the immune system, such as B lymphocytes, where it positively regulates the proliferation of activated T cells. CD24 expression is also described in the central nervous system (Sahlberg et al., 2014) . CD24 + subpopulations from colon cancer cell lines possess stem cell-like properties (Ke et al., 2012) . In contrast, tumour-initiating cells from head and neck and breast cancer have been shown to be CD24 - (Spiegelberg et al., 2013) . CD24 expression has been described not only in haematologic malignancies but also in a large variety of solid tumours, such as breast cancer, prostate cancer, nonsmall-cell lung cancer, nasopharyngeal carcinoma and hepatocellular carcinoma (Takahashi et al., 2013) . There is evidence suggesting proinvasive and prometastatic roles of CD24 in human tumours.
DNA methylation is an epigenetic modification that occurs in both prokaryotes and eukaryotes, which usually takes place at carbon 5 of the cytosine ring within CpG dinucleotides, especially in the promoter region of several genes and noncoding genomic regions. It is involved in a variety of cellular processes, such as gene expression regulation, genome integrity, genomic imprinting, transcriptional regulation, developmental processes and cellular differentiation, and could be modified during tumourigenesis, thus being used as a molecular marker of the tumoural process. Genetic abnormalities involved in the pathogenesis and progression of gastric carcinoma were identified, and several alterations were also correlated with prognosis (Borges et al., 2013) .
p16INK4a genes are tumour suppressors within the locus encompassing the ARF/INK4a genes on chromosome 9p21. Their products regulate the G1-S cell-cycle transition by inhibiting the formation of the cyclin D-CDK 4/6 complex, thus preventing phosphorylation of the retinoblastoma protein (Ye et al., 2014) . Several studies suggest that the altered methylation pattern of the INK4 locus is one of the main reasons for its inactivation in several types of tumours (Borges et al., 2013; Xing et al., 2013; Ye et al., 2014) .
Materials and methods
This is a retrospective study on archival formalin-fixed, paraffin-embedded blocks processed during the years 2002-2009. These blocks were collected from the Pathology Department of Banha University. The cases included gastric cancer specimens (n = 80) and noncancerous gastric tissues (16 chronic gastritis cases with intestinal metaplasia and 20 cases of gastric dysplasia). In addition, 16 apparently normal gastric tissue samples were taken and considered as control. Patient clinicopathological data, such as age, sex, differentiation status, TNM stage and overall survival, were collected from the files of the patients. Thirty-three gastric carcinoma specimens were partial gastrectomy specimens and the other 47 were total gastrectomy specimens. None of the cancerous patients received chemotherapy or radiotherapy before surgery. Patients were followed up for at least 5 years to determine overall survival. Overall survival is defined as the time elapsed from surgery to death of patients with gastric cancer. The University Ethical Committee approved the research protocol.
Pathology
From each block, three sections of 4 mm thickness were cut. One of these sections was stained by haematoxylin and eosin to confirm their histological diagnosis and for other microscopic characteristics such as grade of differentiation, depth of invasion, histologic classification, and vascular invasion. The TNM staging for each gastric carcinoma was evaluated according to the Union Internationale Contre le Cancer (UICC) system for the extent of tumour spread (Zheng et al., 2006) . The other two sections were stained immunohistochemically for CD147 and CD24 study.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue samples were cut into 4 mm serial sections, attached to silane-coated slides, deparaffinized in xylene and rehydrated in PBS (pH 7.4). The deparaffinized sections were boiled for 10 min in 0.01 mol/l citrate buffer (pH 6.0) for antigen retrieval, and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 30 min. Immunohistochemical staining was performed using the EnVision + System/HPR (Dako, Carpentaria, California, USA). The deparaffinized sections were preincubated with normal goat serum to prevent nonspecific binding, and then one slide was incubated for 1.5 h with mouse anti-EMMPRIN (Novocastro, Newcastle, UK; 1 : 50) antibody and the other slide was incubated overnight at 41C with an optimal dilution anti-CD24 antibody (Ab-2, clone 24C02; Neomarkers, Fremont, California, USA). The sections were rinsed with PBS and incubated with peroxidaselabelled polymer for 30 min at room temperature and then washed with PBS. The enzyme reaction was developed with 0.03% 3,3-diaminobenzidine tetrahydrochloride containing 0.006% hydrogen peroxide. Negative controls were obtained by omission of the primary antibodies, and appropriate positive controls were utilized as recommended by the manufacturers.
Evaluation of immunohistochemistry
The immunoreactivity to EMMPRIN was localized in the cytoplasm and membrane. One hundred cells were randomly selected and counted from five representative fields of each section blindly. The positive percentage of counted cells was graded semiquantitatively according to a four-tier scoring system: negative (-), 0-5%; weakly positive (+), 6-25%; moderately positive (+ +), 26-50%; and strongly positive (+ + +), 51-100% (Zheng et al., 2006) .
The cytoplasmic staining intensity of CD24 was scored semiquantitatively as negative (0), weakly positive (+), or moderately/strongly (+ +) positive. Negative cases were defined by complete absence of immunoreactivity in the tumour. A weak staining (+) was defined by a minimal but unequivocal immunoreactivity in upto 10% of the tumour. Any stronger or more extensive staining of the tumour was graded as moderate/strong (+ +) (Jung et al., 2004) .
Polymerase chain reaction-specific methylation DNA extraction and bisulphite treatment
Ten-millimetre-thick paraffin-embedded tissue sections were used for DNA extraction. The paraffin was removed from the tissue by rinsing in xylene, and genomic DNA was isolated using a QIAamp Tissue Kit (Qiagen, Valencia, California, USA). DNA samples were stored at -801C before analysis. DNA (1 mg) was treated with bisulphite to convert unmethylated cytosines to uracils using the EZ DNA Methylation-Gold Kit (Zymo Research Corporation, Irvine, California, USA) according to the manufacturer's protocol. After treatment, the DNA samples were stored at -801C until use.
Methylation-specific polymerase chain reaction MSP Specific primer sets for unmethylated (p16U) and methylated (p16M) DNAs, described by Abbaszadegan et al. (2008) , were utilized. The primers were as follows: unmethylated p16INK4a: 59-TTA TTA GAG GGT GGG GTG GAT TGT-39, 59-CAA CCC CAA ACC ACA ACC ATA A-39, and methylated p16INK4a: 59-TTA TTA GAG GGT GGG GCG GAT CGC-39, 59-GAC CCC GAA CCG CGA CCG TAA-39. The PCR mixture contained 1 Â buffer (Finnzymes OY, Keilaranta, Finland) with 2 mmol/l MgCl 2 , 500 nmol/l each primer, 0.2 mmol/l dNTPs and 1 U Hot Start Taq polymerase (Finzymes). The PCR amplification of the modified DNA samples consisted of one cycle of 951C for 10 min, 40 cycles of 941C for 45 s, 601C for 45s, and 721C for 1 min; then one cycle of 721C for 10 min. DNA from L132 (embryonic lung cell line) cells was used as a positive control for unmethylated DNA. To obtain a positive control for methylated DNA, normal lymphocyte DNA was treated with M.Sss1 CpG methyltransferase (New England BioLabs, Ipswich, UK) before bisulphite treatment. Six microlitres of amplified PCR products were loaded onto 2.5% agarose gels and nondenaturing 8% polyacrylamide gels, stained with ethidium bromide, and directly visualized under UV illumination.
Statistical analyses
Statistical package for the social sciences (SPSS) program (version 16; SPSS Inc., Chicago, Illinois, USA), was used for statistical analysis. The Pearson correlation coefficient was used to correlate CD147 and CD24 expression and methylation status of p16 with clinicopathological data. Values were expressed as mean and SD. P values of 0.05 or less were considered statistically significant, whereas P values greater than 0.05 were considered statistically nonsignificant.
Results
Forty-eight (60%) of the 80 patients with gastric adenocarcinoma were male and 32 (40%) were female. Their ages ranged from 33 to 77 years, with a mean ± SD age of 54.5 ± 11.23 years.
Histologically, 40 (50%) cases were tubular in morphology: 30 (37.5%) were diffuse, and 10 (12.5%) cases were mixed. Forty-four (55%) cases were undifferentiated. Deep invasion beyond the mucosa and submucosa was found in 28 (35%) cases, and 42 (52.5%) cases were associated with lymph node metastasis. Vascular invasion was detected in 60 (75%) cases. Distant metastasis was present in 20 (25%) cases, and 50 (62.5%) cases were in advanced stage (III and IV). Forty-seven (58.75%) cases survived for less than 5 years after tumour resection.
Results of extracellular matrix metalloproteinase inducer (CD147) expression EMMPRIN expression was evident in the cytoplasm and membrane of metaplastic and dysplastic epithelial cells and cancerous cells of the stomach (Figs 1-4 ). As shown in Table 1 , EMMPRIN expression was increased from normal gastric mucosa to carcinoma through metaplastic and dysplastic mucosa (P < 0.05). EMMPRIN expression showed a significantly positive association with tumour depth of invasion, vascular invasion, lymph node metastasis, distant metastasis and TNM staging (P < 0.05). However, CD147 staining was not related to patient sex, age, tumour differentiation or Lauren's classification (P > 0.05). These results indicate that CD147 expression is related to gastric cancer invasion and metastasis. Interestingly, there was a significant positive relationship between EMMPRIN expression and 5-year survival in the gastric carcinomas patients. Most of the patients (73%) who survived for more than 5 years were negative for A case of high-grade gastric dysplasia showing strong brownish inmmunoreactivity of epithelial lining for CD147 (DAB, Â 400). EMMPRIN, CD24 and p16INK4a promoter methylation AbdelMaksoud 55 CD147 expression, whereas 98% of patients with a survival period of less than 5 years were positive for EMMPRIN expression (P < 0.01).
Results of CD24 expression
In normal gastric tissue, CD24 was rarely expressed; only focal cytoplasmic staining of mucosal epithelial cells was seen. CD24 was observed in lymphoid tissue; therefore, it was used as an internal positive control. Two (12.5%) cases of intestinal metaplasia and four (20%) cases of dysplasia displayed weak immunoreactivity against CD24, whereas two (10%) cases of dysplasia showed moderate/strong staining. In contrast, we observed CD24 expression in 44 (55%) cases of gastric adenocarcinoma: 24 (30%) cases showed weak CD24 expression and 20 (25%) cases showed moderate/strong immunoreactivity (Figs 5-7) . In carcinoma cases, there was no significant association of overall CD24 expression with patient sex and age, histologic types of tumours and degree of differentiation or distant metastasis (Table 1) . However, CD24 expression was significantly correlated to the depth of invasion, vascular invasion, lymph node metastasis and TNM stage (P r 0.05) ( Table 2) . Most of the gastric carcinoma cases (77%) who survived for less than 5 years were positive for CD24, whereas most of the cases (76%) who lived for more than 5 years were negative for CD24 (P r 0.01).
Results of p16 methylation
Hypermethylation of the p16 promoter was detected in 52.5% (42/80) of tumoural gastric tissue and in two out of 20 (10%) dysplastic cases, whereas all normal gastric samples were unmethylated. Interestingly, the two dysplastic cases that were hypermethylated were of high grade. MSP analysis of the p16 promoter in gastric cancer is shown in Fig. 8 . There was no association between sex or age and promoter hypermethylation. Methylation was significantly lower in well-differentiated tumours as compared with higher pathological grades (P < 0.05). There was no significant difference in methylation status between intestinal and diffuse types. However, it was detected more in diffuse gastric carcinoma than in tubular cases. p16 promoter methylation had no correlation with depth of invasion, vascular invasion, lymph node metastasis, distant metastasis or TNM stage. A significant correlation was observed between frequency of methylation and 5-year survival. The patients who died before 5 years after resection of gastric carcinoma had more hypermethylation of p16 compared with those who lived for more than 5 years (P < 0.05) (Table 3) .
There was a highly significant correlation between CD147 and CD24 expression (P < 0.01). However, there was no correlation between either of them and methylation status of the p16 promoter (P > 0.05).
Discussion
Controlling tumour progression is one of the most effective strategies to improve prognosis in gastric cancer management. Thus, to administer the most effective treatment and minimize side effects, there is an urgent need for more sensitive markers to predict tumour prognosis.
The crosstalk interaction between tumour cells and adjacent stromal cells participates in tumour immune escape, spreading and angiogenesis, which is conducted by a number of soluble and membrane molecules, including soluble Fas, Fas ligand, soluble MMPs, soluble vascular endothelial growth factor and EMMPRIN (CD147) (Chu et al., 2014) .
In the present study, CD147 protein expression and its association with various clinicopathological aspects including 5-year survival was investigated in 80 cases of gastric cancer. Additional other noncancerous gastric tissue samples (16 with intestinal metaplasia and 20 with gastric dysplasia) were also included in this study. CD147 protein expression was increased in gastric cancer tissues compared with normal tissues, in a stepwise increasing manner from metaplastic to dysplastic lesions to carcinoma. The presence of highly expressed EMMPRIN protein in malignant gastric tissue compared with nonmalignant tissues is in line with the observation made in other studies (Sier et al., 2006; Zheng et al., 2006) . These findings suggest that upregulation of EMMPRIN plays an essential role in the malignant transformation of gastric epithelial cells. Yang et al. (2006) found that EMMPRIN expression in breast carcinoma cells rendered them resistant to apoptosis, triggered by a lack of or improper cell-matrix interactions, mediated by downregulation of the proapoptotic BH3-only protein, through an MAP kinase-dependent pathway. Taken together, the present study supported the opinion that EMMPRIN might enhance tumour growth of gastric carcinomas by disrupting the balance between apoptosis and proliferation.
Stronger positive staining of CD147 was more frequently detected in the present study in gastric cancer with deep invasion, vascular invasion, lymph node metastasis, distant A case of gastric adenocarcinoma grade II showing strong brownish cytoplasmic staining of malignant cells (CD24 immunoreactivity) (DAB, Â 400).
EMMPRIN, CD24 and p16INK4a promoter methylation AbdelMaksoud 57 metastasis and advanced TNM stage, which was consistent with previous studies (Zheng et al., 2006; Chu et al., 2014) . However, CD147 expression was not correlated with age, sex, differentiation status or Lauren's classification. Wang et al. (2010) suggested that downregulation of CD147 decreased cell proliferation, MMP-2 and MMP-9 activities and the invasive potential of SGC7901 cells, which support the results of the current study. Taken together, these data suggest that CD147 Fig. 7 A case of poorly differentiated gastric carcinoma showing moderate brownish cytoplasmic staining of malignant cells (CD24 immunoreactivity) (DAB, Â 400). might be involved in gastric cancer progression. Elevated EMMPRIN expression has also been shown to correlate with the progression of various other malignancies (Sier et al., 2006; Van der Jagt et al., 2006; Xue et al., 2011; Monteiro et al., 2014) .
The association of CD147 with gastric cancer invasion and metastasis may be at least partially due to its effect on MMPs, as MMPs permit cells to actively remodel the ECM. CD147 is known to promote tumour invasion and metastasis by stimulating MMP synthesis in neighbouring fibroblasts (Luo et al., 2009) . In this perspective, CD147 stimulates the production of MMPs, which could degrade the ECM and facilitate tumour cell invasion and metastasis.
Recent studies also demonstrated that EMMPRIN not only induces different MMPs but also regulates parameters of the urokinase plasminogen activator system and vascular endothelial growth factor (Lescaille et al., 2012) .
Because CD147 is associated with gastric cancer invasion and metastasis, its association with 5-year overall survival was also studied.
The current study revealed significantly worse overall survival for patients with CD147 + tumours, indicating that CD147 protein level is a marker of prognosis for patients with gastric cancer.
The present study showed no association between EMMPRIN expression and carcinoma differentiation.
In a study carried out by Zheng et al. (2006) , it was worth noting that EMMPRIN was weaker in the welldifferentiated cell line (MKN28) than in the poorly differentiated (MNK45) or undifferentiated ones (HGC-27), although there was no statistically significant difference.
In conclusion, upregulated expression of EMMPRIN might contribute to tumourigenesis, growth, local invasion and distant metastasis of gastric carcinoma. It could thus be considered an effective marker to predict the invasion and prognosis of gastric carcinoma.
CD24 is a glycoprotein involved in differentiation and apoptosis in the immune system as well as in migration in the nervous system. The functions of CD24 are, however, less well characterized in the gastrointestinal tract, although some authors have proposed that CD24 is expressed within subpopulations of gastric and colon cancer stem cells and that CD24 acts as a potential marker or regulator of stem cells in the gastrointestinal tract (Clyde and Pritchard, 2012) .
In the present study CD24 protein expression was immunohistochemically examined. Positive CD24 expression was found in more than half of gastric carcinoma cases. Moreover, CD24 expression was significantly correlated with depth of invasion, vascular invasion, lymph node metastasis and TNM stage: all factors associated with tumor progression. This metastatic EMMPRIN, CD24 and p16INK4a promoter methylation AbdelMaksoud 59 potential of CD24 + tumour cells can be explained as that, on tumour cells, CD24 acts as a ligand for P-selectin. P-selectin is expressed by activated platelets and endothelial cells. Tumour cells can bind to platelets and endothelial cells through CD24-P-selectin interaction, so that CD24-expressing tumour cells can disseminate more easily because of their capacity to form thrombi with activated platelets, or to adhere to endothelia in the bloodstream (Fujikuni et al., 2014) .
The correlation between CD24 expression and invasiveness had been reported in mammary carcinoma cell lines and bladder transitional carcinoma tissues. Also, overexpression of CD24 in the glioma cell line stimulated the migration and invasion of tumour cells (Jung et al., 2004) .
In oesophageal cancer, CD24 expression was associated with depth of invasion and lymph node metastases (Sano et al., 2009) . Also CD24 expression in colorectal and breast cancer was reported to correlate with nodal metastasis (Sagiv et al., 2006; Athanassiadou et al., 2009 ). Darwish et al. (2004) demonstrated that positive CD24 expression occurs in a subset of gastric carcinomas and that it correlates significantly with lymphatic invasion, blood vessel invasion and poor survival. Also Takahashi et al. (2013) found that CD24 expression was upregulated in gastric samples with increased nodal metastasis. Wang et al. (2014) indicated that CD24 mediates gastric carcinogenesis and may promote gastric carcinoma progression by suppressing apoptosis and promoting invasion.
It was also reported that CD24 is a cancer stem cell marker. Lawson et al. (2007) proposed a cell surface profile consisting of many cell markers that characterizes prostate cancer stem cells; these cells are also CD24 + . Li et al. (2007) found that CD44 + , CD24 + pancreatic cancer stem cells were 100-fold more tumourigenic than other cells. Stationary cancer stem cells exist in differentiated central areas of carcinomas (Brabletz et al., 2005) . Following the epithelial-mesenchymal transition, cancer stem cells migrate a short distance to establish focal extension or invade through blood or lymphatic vessels to produce longdistance dissemination and eventual metastasis. We speculate that, if CD24 is increased, epithelial-mesenchymal transition and metastasis are more progressive.
In contrast, Taguchi et al. (2003) reported that the crosslinking of CD24 induces apoptosis in Burkett's lymphoma enhanced by a B-cell antigen receptor (BCR)-mediated signaling. Furthermore, proliferation of human colorectal and pancreatic cancer cell lines can be inhibited by CD24specific antibodies (Takahashi et al., 2013) .
In conclusion, increased expression of CD24 in gastric cancer may be correlated with poor prognosis. This study suggests that patients with CD24 + gastric cancer should be monitored after resection to reduce the risk of postoperative progression. Moreover, CD24 may provide a new molecular target for improving therapeutic strategies for CD24 + gastric cancer.
Several genetic and epigenetic alterations play an important role in gastric carcinogenesis. Tumour suppressor and other tumour-related genes are the main targets.
Aberrant alterations of p16, as a tumour suppressor gene, are important events in several tumours, including gastric cancer (Borges et al., 2013) . In this study, we demonstrated that 52.5% of tissues from gastric adenocarcinoma were methylated. The methylation rate of the p16 genes increased from normal gastric biopsy specimens to gastric dysplasia to gastric cancer tissue. Interestingly, the two dysplastic cases that showed aberrant methylation were of high grade. Follow-up data on these cases were not available to clarify whether they converted to overt carcinoma.
This result was consistent with those of previous studies by Abbaszadegan et al. (2008) , Hu et al. (2010) and Borges et al. (2013) . These findings suggest that promoter hypermethylation of the p16 gene is frequent in gastric cancer and may be an early molecular event in gastric carcinogenesis.
In the present study, hypermethylation of p16 was less frequent in well-differentiated tumours; thus, p16 promoter hypermethylation may be associated with tumour malignant behaviour. There were no significant differences in methylation status between histologic types of gastric carcinoma; however, the diffuse subtype was strongly associated with promoter hypermethylation.
In the patients studied, low overall survival was associated with more frequent hypermethylation of the p16 promoter. Other studies demonstrate that 5-fluorouracil, an antimetabolite agent widely used in adjuvant chemotherapy, correlates with significant disease-free survival, indicating that cells with p16INK4a hypermethylation might be more sensitive to adjuvant 5-fluorouracil treatment than those without methylation (Mitsuno et al., 2007) .
In conclusion, CpG island hypermethylation of the p16 promoter is frequent in gastric cancer and may be an early molecular event in its development. Further studies are warranted to determine whether promoter hypermethylation in precancerous gastric lesions is associated with a higher risk for subsequent cancer development, and to interrupt the malignant transition from intestinal metaplasia and gastric epithelial dysplasia to early gastric adenocarcinoma by developing gene targeting therapies that may reverse aberrant methylation.
